V Rodrigues1, F Landi2,3, S Castro2, R Mast4, N Rodríguez2, A Gantxegi2, J Pradell2, M López-Cano2, M Armengol2. 1. General and Digestive Surgery Department, Vall d´Hebron University Hospital, Universitat Autònoma de Barcelona (UAB), 119-129, 08035, Barcelona, Spain. vrodrigues@vhebron.net. 2. General and Digestive Surgery Department, Vall d´Hebron University Hospital, Universitat Autònoma de Barcelona (UAB), 119-129, 08035, Barcelona, Spain. 3. Department of HPB and Transplant Surgery, Hospital Clinic, Universidad de Barcelona, Barcelona, Spain. 4. Institut de Diagnostic per la Imatge, Vall d´Hebron University Hospital, Barcelona, Spain.
Abstract
BACKGROUND: The prognostic value of sarcopenic obesity in gastric cancer surgery remains debated. We aimed to evaluate the impact on outcomes of body composition and sarcopenic obesity after gastrectomy for gastric cancer. METHODS: A retrospective review of prospectively maintained database of patients undergoing gastrectomy for gastric cancer from 2010 to 2017 was performed. Skeletal muscle mass and visceral adipose tissue were evaluated by preoperative computed tomography to define sarcopenia and obesity. Patients were classified in body composition groups according to the presence or absence of sarcopenia and obesity. Prognostic factors for survival were assessed by multivariate Cox analysis. RESULTS: Of the 198 patients undergoing gastrectomy for gastric cancer, 90 (45.4%) patients were sarcopenic, 130 (67.7%) obese, and in the subclassification for body composition categories: 33 (17%) nonsarcopenic nonobesity, 75 (38%) non sarcopenic obesity, 35 (17%) sarcopenic nonobesity, and 55 (28%) sarcopenic obesity. No category of body composition was a predictor of postoperative complications and worse overall and disease-free survival outcomes. Multivariable analysis identified ASA III classification, preoperative weight loss > 10%, postoperative surgical re-intervention, and advanced tumor stage as independent prognostic factors for overall survival, and patients aged 75 years or older, preoperative weight loss > 10%, elevated netrophil-lymphocyte ratio, and advanced tumor stage as independent prognostic factors for disease-free survival. CONCLUSIONS: Sarcopenia, obesity, and sarcopenic obesity were not associated with worse outcomes after gastric cancer surgery.
BACKGROUND: The prognostic value of sarcopenic obesity in gastric cancer surgery remains debated. We aimed to evaluate the impact on outcomes of body composition and sarcopenic obesity after gastrectomy for gastric cancer. METHODS: A retrospective review of prospectively maintained database of patients undergoing gastrectomy for gastric cancer from 2010 to 2017 was performed. Skeletal muscle mass and visceral adipose tissue were evaluated by preoperative computed tomography to define sarcopenia and obesity. Patients were classified in body composition groups according to the presence or absence of sarcopenia and obesity. Prognostic factors for survival were assessed by multivariate Cox analysis. RESULTS: Of the 198 patients undergoing gastrectomy for gastric cancer, 90 (45.4%) patients were sarcopenic, 130 (67.7%) obese, and in the subclassification for body composition categories: 33 (17%) nonsarcopenic nonobesity, 75 (38%) non sarcopenic obesity, 35 (17%) sarcopenic nonobesity, and 55 (28%) sarcopenic obesity. No category of body composition was a predictor of postoperative complications and worse overall and disease-free survival outcomes. Multivariable analysis identified ASA III classification, preoperative weight loss > 10%, postoperative surgical re-intervention, and advanced tumor stage as independent prognostic factors for overall survival, and patients aged 75 years or older, preoperative weight loss > 10%, elevated netrophil-lymphocyte ratio, and advanced tumor stage as independent prognostic factors for disease-free survival. CONCLUSIONS:Sarcopenia, obesity, and sarcopenic obesity were not associated with worse outcomes after gastric cancer surgery.
Authors: Y Zhang; J P Wang; X L Wang; H Tian; T T Gao; L M Tang; F Tian; J W Wang; H J Zheng; L Zhang; X J Gao; G L Li; X Y Wang Journal: Curr Oncol Date: 2018-10-31 Impact factor: 3.677
Authors: Kai A Bickenbach; Brian Denton; Mithat Gonen; Murray F Brennan; Daniel G Coit; Vivian E Strong Journal: Ann Surg Oncol Date: 2012-09-14 Impact factor: 5.344
Authors: Y H M Claassen; H H Hartgrink; J L Dikken; W O de Steur; J W van Sandick; N C T van Grieken; A Cats; A K Trip; E P M Jansen; W M Meershoek-Klein Kranenbarg; J P B M Braak; H Putter; M I van Berge Henegouwen; M Verheij; C J H van de Velde Journal: Eur J Surg Oncol Date: 2018-02-09 Impact factor: 4.424
Authors: W D Dewys; C Begg; P T Lavin; P R Band; J M Bennett; J R Bertino; M H Cohen; H O Douglass; P F Engstrom; E Z Ezdinli; J Horton; G J Johnson; C G Moertel; M M Oken; C Perlia; C Rosenbaum; M N Silverstein; R T Skeel; R W Sponzo; D C Tormey Journal: Am J Med Date: 1980-10 Impact factor: 4.965
Authors: Edmund K Bartlett; Robert E Roses; Rachel R Kelz; Jeffrey A Drebin; Douglas L Fraker; Giorgos C Karakousis Journal: Surgery Date: 2014-03-16 Impact factor: 3.982